Nexentis subsidiary MitoCareX orders molecules for planned in-vitro testing
NXTS•Nexentis subsidiary MitoCareX Bio ordered molecules for planned in-vitro evaluation after additional computational prioritization. The molecules have not arrived, and testing has not begun.




